20:20:03 EST Mon 16 Nov 2026
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save
Cipher Pharmaceuticals Inc
Symbol CPH
Shares Issued 26,985,716
Close 2020-04-20 C$ 0.73
Market Cap C$ 19,699,573
Recent Sedar+ Documents

Cipher wins arbitration case against Upsher-Smith

2020-04-20 20:08 ET - News Release

Mr. Craig Mull reports

CIPHER PHARMACEUTICALS RECEIVES POSITIVE RULING ON BINDING ARBITRATION WITH UPSHER-SMITH LABORATORIES

Cipher Pharmaceuticals Inc. has been successful in its binding arbitration with Upsher-Smith Laboratories LLC.

On Dec. 19, 2018, the company received a paragraph 4 certification notice of filing advising Sun Pharmaceuticals Inc. and Galephar Pharmaceuticals Research Inc. that Upsher-Smith filed an abbreviated new drug application (ANDA) with the Food and Drug Administration seeking approval to manufacture, use or sell a generic version of Absorica (10 milligrams, 20 milligrams and 30 milligrams) prior to the expiration of U.S. patent No. 7,435,427; 8,367,102; 8,952,064; 9,078,925; and 9,089,534. Upsher-Smith subsequently filed a second ANDA seeking approval to manufacture, use or sell a generic version of Absorica (40 milligrams).

On Jan. 30, 2019, Galephar, Cipher and Sun Pharma initiated a patent infringement lawsuit against Upsher-Smith, alleging Upsher-Smith had infringed on at least one or more of their patents by filing an abbreviated new drug application with the Food and Drug Administration to market a generic version of Absorica.

"Today's decision in the binding arbitration reinforces the strength of our patents and will delay Upsher-Smith's entry into the market until June 25, 2021," said Craig Mull, interim chief executive officer. "This binding arbitration, along with the previously announced Absorica brand extension program, place the company in a strong position to benefit from the future revenue stream associated with Absorica and Absorica LD," added Mr. Mull.

About Cipher Pharmaceuticals Inc.

Cipher Pharmaceuticals is a specialty pharmaceutical company with a robust and diversified portfolio of commercial and early- to late-stage products. Cipher acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and currently markets those products either directly in Canada or indirectly through partners in Canada, the United States and South America.

We seek Safe Harbor.

© 2026 Canjex Publishing Ltd. All rights reserved.